Nothing Special   »   [go: up one dir, main page]

Nolting et al., 1992 - Google Patents

Double‐blind comparison of amorolfine and bifonazole in the treatment of dermatomycoses

Nolting et al., 1992

Document ID
16496301918194799777
Author
Nolting S
Semig G
Friedrich H
Dietz M
Reckers‐Czaschka R
Bergstraesser M
Zaug M
Publication year
Publication venue
Clinical and Experimental Dermatology

External Links

Snippet

A total of 232 patients with mycoses of skin folds, body, or feet were entered into a double‐ blind, parallel group‐study. Therapy with 0· 125, 0· 25, 0· 5% amorolfine cream or 1% bifonazole cream was randomly allocated to patients. The cream was applied once daily for …
Continue reading at academic.oup.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients

Similar Documents

Publication Publication Date Title
Lauharanta Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly
Buck et al. Comparison of two topical preparations for the treatment of onychomycosis: Melaleuca alternifolia (tea tree) oil and clotrimazole
Villars et al. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases
Hay et al. Tioconazole nail solution—an open study of its efficacy in onychomycosis
Reinel et al. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once‐weekly versus twice‐weekly
Khosravi et al. Onychomycosis in Tehran, Iran: prevailing fungi and treatment with itraconazole
Ghannoum et al. Evaluation of antifungal efficacy in an optimized animal model of Trichophyton mentagrophytes-dermatophytosis
Del Palacio Hernanz et al. A comparative double‐blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris
Batter et al. Skin and Nail Mycoses: Treatment with Ketoconazole, a New Oral Antimycotic Agent: Haut‐und Nagelmykosen: Behandlung mit Ketoconazole, einem neuen oralen Antimykotikum
Nolting et al. Double‐blind comparison of amorolfine and bifonazole in the treatment of dermatomycoses
Crissey Common dermatophyte infections: a simple diagnostic test and current management
Banerjee et al. Comparative evaluation of efficacy and safety of topical fluconazole and clotrimazole in the treatment of tinea corporis.
Hay et al. Itraconazole in the management of chronic dermatophytosis
CLAYTON et al. A clinical double‐blind trial of topical miconazole* and clotrimazole† against superficial fungal infections and erythrasma
Kashin et al. A comparative study of once versus twice daily treatment of superficial dermatophyte and yeast infections with tioconazole (1%) cream
Pal et al. Etiology, clinical spectrum, epidemiology, new developments in diagnosis and therapeutic management of onychomycosis: An update
del Palacio et al. Topical treatment of tinea corporis and tinea cruris with eberconazole (WAS 2160) cream 1% and 2%: a phase II dose‐finding pilot study: Topische Behandlung der Tinea corporis und Tinea cruris mit Eberconazol‐(WAS 2160)‐1% und‐2%‐Creme: Eine Phase‐II‐Dosisfindungsstudie
Kaur et al. Efficacy, safety, and cost evaluation of the topical luliconazole therapy versus topical clotrimazole therapy in patients with localized dermatophytosis in a tertiary care hospital: An observational study
Decroix Tinea pedis (mocassin-type) treated with itraconazole.
Albert et al. Management of onychomycosis with topicals
Kawai Characteristics and Efficacy of Two Topical Therapeutic Agents for Onychomycosis Efinaconazole 10% Solution and Luliconazole 5% Solution
Bodman et al. Topical treatments for onychomycosis: a historical perspective
WO2024011868A1 (en) Use of vanillyl butyl ether in preparation of products for treating dandruff and tinea corporis
Del Palacio et al. Dose‐finding study of amorolfine cream (0· 125%, 0· 25% and 0· 5%) in the treatment of dermatomycoses
Gupta et al. Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double-blind placebo-controlled study